L&T-TECHNOLOGY
15.3.2024 04:16:26 CET | Business Wire | Press release
L&T Technology Services Limited (LTTS) (BSE: 540115, NSE: LTTS), a leading global pure-play engineering and technology services company, announced today that it has won a first-of-its-kind program in India worth around $100 million from Maharashtra State Cyber Department, under the Government of Maharashtra. This initiative extends LTTS’ commitment to developing secure, digitally interconnected smart and safe cities through premier Cyber Security and Digital Forensic solutions consolidated under one umbrella.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314467779/en/
First-of-its-kind program in India entails designing a sophisticated cybersecurity system using AI & Digital Forensic tools. (Photo: Business Wire)
In this pioneering initiative by the Government of Maharashtra, LTTS in consortium with M/s KPMG Assurance and Consulting Services LLP as forensics partner will provide advanced Cyber Security Solutions for the State enhancing public safety against cyber threats.
The project entails designing a sophisticated cybersecurity system and establishing a state-of-the-art, fully equipped, Cyber security and Cybercrime prevention Centre to address Cybercrime Incidents and Investigations by leveraging AI and Digital Forensic tools. The program also encompasses the following:
- A Digital Threat Analytics Centre (DTAC) paired with a Centre of Excellence (COE) that will equip the forensic team with cutting edge digital forensic tools including Deepfake detection, Mobile Malware forensics, IoT investigation, Network forensics, object detection supporting crypto & blockchain, Hardware & Embedded forensics, drone forensics, social media forensics, image enhancement, voice analysis labs, IMEI/CDR analysis, CCTV acquisition tools and computer forensics to streamline crime scene management, reduce timelines and improve the efficiency of cybercrime investigations.
- A Central Emergency Response Team (CERT) to deal with incident response and investigation based on advanced cyber threat intelligence and analytics like APT detection and data breach, adversary intelligence from darknet, advanced malware analysis, proactive threat hunting and red teaming.
- State-of-the-art Security Operations Centre (SOC) fortified by AI & ML technologies with a skilled cyber team to protect critical infrastructure. SOC handles Endpoint Detection & Response, SIEM, SOAR, UEBA, ZTNA, CASB, DLP, NAC, DNS Security, IDAM, and PAM solutions.
The integration of Smart World and Communication within LTTS has significantly amplified its capabilities, enabling the company to provide advanced engineering solutions for public cyber safety leveraging experience of setting up 25+ command centers. The successful execution of this project in India will pave the way for LTTS to extend these capabilities globally.
Commenting on the milestone win, Amit Chadha, CEO and Managing Director of L&T Technology Services, said, "This first-of-its-kind deal is more than just a business achievement for us. It’s an opportunity to leverage our experience in setting up over 25 command centers and recognizing the growing criticality of cybersecurity and the need to invest in advanced digital safeguard platforms and tools for the benefit of the larger society. This deal will set the stage for LTTS to scale its offerings for our global clientele.”
M/s KPMG Assurance and Consulting Services LLP., as LTTS' consortium partner, has played a critical role in this engagement. Yezdi Nagporewalla, Chief Executive Officer, KPMG in India, said, "We are truly proud to be part of this groundbreaking initiative. Collaborating with Maharashtra State Cyber Department and LTTS as a forensic services partner is a matter of pride for KPMG and it showcases our shared commitment to public safety by providing advanced cyber security solutions to counter cyber threats."
ABOUT L&T TECHNOLOGY SERVICES
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,200 employees spread across 22 global design centers, 28 global sales offices and 105 innovation labs as of December 31, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314467779/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
